News - Shire, Vpriv


Current filters:


Popular Filters

Shire's Vpriv shows significant improvement in Gaucher-related bone disease


Shire's Vpriv shows significant improvement in Gaucher-related bone disease

PharmaceuticalRare diseasesResearchShireVpriv

Elelyso: a new therapeutic option for patients with Gaucher disease


The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

GSK inks $300m rare diseases alliance with Angiochem


GlaxoSmithKline has forged an R&D alliance with Montreal, Canada-based Angiochem that will focus on the…

AngiochemCerezymeGenzymeGSKNeurologicalPharmaceuticalRare diseasesShireVpriv

EMA approves Shire Vpriv plant in USA


Ireland-headquartered biopharma firm Shire (LSE: SHP) says that the European Medicines Agency's Committee…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseasesRegulationReplagalShireVpriv

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv


Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top